260) The maximum effect was observed at 150 mg/kg that reduced the frequency of MN from 12.78 ± 0.24% for DZN group to 5.61 ± 0.17%. |
PMID:23843223 DOI:10.1177/0748233713491811 |
2015 Toxicology and industrial health |
* The chemoprotective effects of L-carnitine against genotoxicity induced by diazinon in rat blood lymphocyte. |
- The purpose of this study was to assess the preventive effects of L-carnitine (LC) against DNA damage induced by diazinon (DZN) in rat blood lymphocytes. Animals were concurrently administered intraperitoneally with DZN in proper solvent (20 mg/kg body weight (b.w.)) and LC at three different doses (50, 100, and 150 mg/kg b.w.) for 30 consecutive days. The positive control group received DZN at the same dose without LC. Twenty-four hour after last injection, 0.5 ml blood of each rat was received and cultured in culture medium for 44 h. The lymphocyte cultures were mitogenically stimulated with cytochalasin B for the evaluation of the number of micronuclei (MNs) in cytokinesis-blocked binucleated cells. Incubation of lymphocytes with DZN induced additional genotoxicity and was shown by increase in MNs frequency in rat lymphocytes. LC at all doses had a protective effect and significantly reduced the MNs frequency in cultured lymphocytes (p < 0.0001-p < 0.05). The maximum effect was observed at 150 mg/kg that reduced the frequency of MN from 12.78 ± 0.24% for DZN group to 5.61 ± 0.17%. Our study revealed that LC has a potent antigenotoxic effect against DZN-induced toxicity in rats, which may be due to the scavenging of free radicals and increased antioxidant status. Since LC is a natural compound and is being safe, it is recommended as a daily supplement for body defense against side effects induced by chemical hazardous agents. |
(1)49 *null* | (15)7 received | (29)3 II | (44)2 difference |
(2)33 was | (16)5 at | (30)3 after | (45)2 displayed |
(3)29 and | (17)5 for | (31)3 comprised | (46)2 dynamics-based |
(4)25 of | (18)5 the | (32)3 in | (47)2 exhibited |
(5)16 compared | (19)5 to | (33)3 when | (48)2 however, |
(6)12 A | (20)4 (p | (34)2 (30 | (49)2 improved |
(7)12 were | (21)4 B | (35)2 (n | (50)2 included |
(8)11 discussions | (22)4 C | (37)2 B, | (51)2 intervention |
(9)10 than | (23)4 differences | (38)2 III | (52)2 interventions |
(10)9 I | (24)4 or | (39)2 V | (53)2 interviews |
(11)8 had | (25)3 1, | (40)2 a | (54)2 patients |
(12)8 showed | (26)3 2 | (41)2 as | (55)2 presented |
(13)8 with | (27)3 4 | (42)2 contains | (56)2 that |
(14)7 1 | (28)3 A, | (43)2 demonstrated |
add keyword